Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ --

- Study Triggers $7.5m Milestones for Both Companies

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The study has now appeared on clinicaltrials.gov and will be recruiting in the next few weeks when the first patient first visit will trigger a $7.5 million milestone payment to both Sosei and Vectura.

The trial is a randomised, double-blind, placebo-controlled, parallel-group design, including an open-label tiotropium bromide arm, and will assess efficacy, safety and tolerability of NVA237 in patients with COPD. It will include approximately 1000 patients with moderate to severe COPD from study centres across the USA, Europe and other territories. Each patient will be randomised to receive a once-daily dose of placebo, tiotropium bromide or 50microg of NVA237 for a 52-week period. The primary endpoint of the study will be the change from baseline in FEV1 (forced expiratory volume in one second) over 12 weeks of treatment. A number of secondary endpoints will also be evaluated.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Novartis intends to launch NVA237 as a once-daily monotherapy for COPD and also in combination with Novartis' investigational once-daily, long-acting beta2-agonist (LABA) indacaterol (QAB149), which was filed for approval with the regulatory authorities as a monotherapy treatment for COPD at the end of 2008. The combination of NVA237 and indacaterol is known as QVA149. NDA submissions
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 26, 2011 Revenue of $374 million grew 5 ... share were $0.55 compared to $0.31 in the prior year, an increase of ... points to 13.3 percent Fiscal year 2011 ... 7 percent and earnings are expected to be $2.18 to $2.26 per diluted ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... 31, 2010. The Company reported total revenue of $174.2 ... net product sales of $162.3 million and revenue under ... $22.9 million for the quarter ended December 31, 2010, ...
Cached Medicine Technology:Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 2Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 3Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 4Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 5Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 6Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 7Hill-Rom Reports 77 Percent Growth in First Quarter Earnings Per Share 8Amylin Pharmaceuticals Reports 2010 Financial Results 2Amylin Pharmaceuticals Reports 2010 Financial Results 3Amylin Pharmaceuticals Reports 2010 Financial Results 4Amylin Pharmaceuticals Reports 2010 Financial Results 5Amylin Pharmaceuticals Reports 2010 Financial Results 6Amylin Pharmaceuticals Reports 2010 Financial Results 7Amylin Pharmaceuticals Reports 2010 Financial Results 8Amylin Pharmaceuticals Reports 2010 Financial Results 9
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Grieving children from northern Allegheny, Armstrong, Beaver, Butler, ... to be served at new facility, PITTSBURGH, Feb. ... Children, Adolescents and Their Families, announced today its,intention to ... Cranberry,area, which will aim to serve children and families ...
... For years, getting a lot of,calcium has been ... do to,prevent osteoporosis and related bone fractures. Small study ... the data from,large, prospective studies that followed people for ... 2008 issue of the Harvard,Health Letter., The ambiguity ...
... Americans who,are unaware they have diabetes or are at ... Risk Test, ALEXANDRIA, Va., Feb. 25 The ... WHAT: The American Diabetes Association will "sound the alert" ... Tuesday, March 25,2008. American Diabetes Alert Day is a ...
... reducing cross contaminations including Influenza and ... ... today introduced,the new SILVER SEAL(TM) Washable, Antimicrobial Mouse at the HiMSS,Healthcare Symposium ... world,s first computer mouse to be fully submersible,dishwasher safe, and manufactured from ...
... With Standardized Pomegranate Extract and Pomegranate Seed Oil ... and Cell Protecting Benefits, EL SEGUNDO, Calif., ... use of,pomegranate in skincare for anti-inflammatory, antioxidant and ... equal; it is,the quality of the extract that ...
... AS PART OF ... SMART HEART CHALLENGE CAMPAIGN, CHICAGO, Feb. 25 Quaker ... hearts. Thanks to thousands of,Americans who signed up to take the ... King Cardiac Foundation (LKCF).,As part of this heart healthy campaign to ...
Cached Medicine News:Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 2Health News:Highmark Caring Place to Expand Services to New Facility in Cranberry Area 3Health News:High Calcium Intake May Not Help Prevent Fractures, Reports The Harvard Health Letter 2Health News:Sound the Alert!!! - March 25 is the 20th Annual American Diabetes Alert(R) Day 2Health News:Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 2Health News:Super Charge the Skin with Murad Vitalic(R) Featuring Energizing Pomegranate Complex(TM) 3Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 2Health News:King of Talk Celebrates Milestone With Quaker, The King of Hearts 3
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... range of Platelet aggregometers allows to ... particular needs. Single, dual and four ... recorder outputs or digital computer outputs. ... aggregometers, which measure platelet aggregation in ...
... in achieving improved cost efficiency in ... cut costs is constantly increasing. Optimize ... unnecessary manual interactions. Ensuring security of ... mechanisms like pipetting integrity check. Right ...
... The Advia 2400 ... sample volume (as low ... water consumption (40 L/hour) ... The optional universal rack ...
Medicine Products: